Abbott drug shows improvement in young adults with arthritis

Drug maker announces results of phase-3 trial of Humira in nr-axSpA

ABBOTT PARK, Ill. — Patients with a form of arthritis that affects young adults taking a drug made by Abbott experienced improvements in their condition after a year of treatment, according to late-stage clinical trial results.

Abbott announced Monday the first long-term patient-reported health outcomes data for the phase-3 "ABILITY-1" trial of Humira (adalimumab) in patients with nonradiographic axial spondyloarthritis, or nr-axSpA. Results of the trial were presented at the American College of Rheumatology's annual scientific meeting in Washington.

The study showed that patients taking Humira experienced improvement in physical function and measures of health-related quality of life after 52 weeks.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.